AR052772A1 - Formas cristalinas y proceso para preparar compuestos de espiro-hidantoina - Google Patents
Formas cristalinas y proceso para preparar compuestos de espiro-hidantoinaInfo
- Publication number
- AR052772A1 AR052772A1 ARP050104164A ARP050104164A AR052772A1 AR 052772 A1 AR052772 A1 AR 052772A1 AR P050104164 A ARP050104164 A AR P050104164A AR P050104164 A ARP050104164 A AR P050104164A AR 052772 A1 AR052772 A1 AR 052772A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- heteroaryl
- aryl
- alkyl
- heterocycle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
Abstract
El proceso incluye opcionalmente la separacion enantiomérica de los intermediarios para permitir la preparacion de enantiomeros de los compuestos de espiro-hidantoina de la formula (1). Los compuestos de espiro-hidantoina sustituidos pueden ser preparados a partir de los compuestos de espiro-hidantoina de la formula (1). El compuesto de espiro-hidantoina de la formula (1) y los compuestos de espiro-hidantoina sustituidos son utiles en el tratamiento de enfermedades inmunes o inflamatorias. También, se proporcionan los productos elaborados mediante el presente proceso y las formas cristalinas del compuesto de espiro-hidantoina sustituido, el ácido 5-[(5S, 9R)-9-(4-cianofenil)-3-(3,5-diclorofenil)-1-metil-2,4-dioxo-1,3,7- triazaspiro[4.4]non-7-ilmetil]-tiofen-3-carboxílico, incluyendo los solvatos y sales del mismo, así como los métodos de uso del mismo. Se proporcionan también las formas cristalinas de ciertos intermediarios. Reivindicacion 1: Un proceso para preparar un de formula (1) de espiro-hidantoina, caracterizado porque comprende: poner en contacto el compuesto de formula (2) de alqueno, con: i) un compuesto precursor de metileno; y ii) glicina o éster de glicina, en presencia de solvente polar para proporcionar el compuesto de espiro-hidantoina de formula (1) o una sal, hidrato, solvato o profármaco farmacéuticamente aceptables del mismo; en donde: L y K son independientemente O o S; Z es N o CR4b; Ar es arilo, arilo sustituido, heteroarilo o heteroarilo sustituido; G es un enlace, -O-, -S-, -NR1, alquileno C1-3, alquileno sustituido C1-3, alcoxi bivalente, tioalquilo, aminoalquilo, sulfonilo, sulfonamidilo, acilo, o alcoxicarbonilo; R1 es hidrogeno, alquilo o alquilo sustituido; R2 es hidrogeno, alquilo, alquilo sustituido, -OR12, -NR12R13, -C(=O)R12, -CO2R12, -C(=O)NR12R13, -NR12C(=O)R13, -NR12C(=O)OR13, -S(O)pR13a, -NR12SO2R13a, -SO2NR1213, cicloalquilo, cicloalquilo sustituido, heterociclo, heterociclo sustituido, arilo, arilo sustituido, heteroarilo o heteroarilo sustituido; R4a, R4b y R4c son independientemente hidrogeno, halogeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, nitro, ciano, -SR14, -OR14, -NR14R15, -NR14C(=O)R15, - CO2R14, -C(=O)R14, C(=O)NR14R15, arilo, arilo sustituido, heterociclo, heterociclo sustituido, cicloalquilo, cicloalquilo sustituido, heteroarilo, y/o heteroarilo sustituido; R12, R13, R14 y R15 son independientemente hidrogeno, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterociclo, y/o heterociclo sustituido; o ii) R12 es tomado junto con R13, y/o R14 es tomado junto con R15 para formar un heteroarilo, heteroarilo sustituido, heterociclo o heterociclo sustituido; R13a es alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterociclo, o heteroarilo sustituido; y p es 1 o 2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61529204P | 2004-10-01 | 2004-10-01 | |
US61790504P | 2004-10-12 | 2004-10-12 | |
US71729005P | 2005-09-15 | 2005-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052772A1 true AR052772A1 (es) | 2007-04-04 |
Family
ID=35789058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050104164A AR052772A1 (es) | 2004-10-01 | 2005-09-30 | Formas cristalinas y proceso para preparar compuestos de espiro-hidantoina |
Country Status (7)
Country | Link |
---|---|
US (2) | US7381737B2 (es) |
EP (1) | EP1802628A1 (es) |
JP (1) | JP2008514729A (es) |
AR (1) | AR052772A1 (es) |
PE (1) | PE20060578A1 (es) |
TW (1) | TW200616634A (es) |
WO (1) | WO2006039639A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7199125B2 (en) * | 2003-10-02 | 2007-04-03 | Bristol-Myers Squibb Company | Spiro-cyclic compounds useful as anti-inflammatory agents |
EP1682537B1 (en) | 2003-11-05 | 2012-03-28 | SARcode Bioscience Inc. | Modulators of cellular adhesion |
TW200616634A (en) * | 2004-10-01 | 2006-06-01 | Bristol Myers Squibb Co | Crystalline forms and process for preparing spiro-hydantoin compounds |
US8110581B2 (en) | 2004-11-10 | 2012-02-07 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
ES2547724T3 (es) * | 2004-11-10 | 2015-10-08 | Incyte Corporation | Compuestos de lactama y su uso como productos farmacéuticos |
US7186727B2 (en) * | 2004-12-14 | 2007-03-06 | Bristol-Myers Squibb Company | Pyridyl-substituted spiro-hydantoin compounds and use thereof |
US20060142319A1 (en) * | 2004-12-14 | 2006-06-29 | Bang-Chi Chen | Pyridyl-substituted spiro-hydantoin crystalline forms and process |
CN101304976A (zh) * | 2005-10-11 | 2008-11-12 | 因特蒙公司 | 病毒复制抑制剂 |
AU2008216382A1 (en) * | 2007-02-12 | 2008-08-21 | Array Biopharma, Inc. | Novel inhibitors hepatitis C virus replication |
WO2008136393A1 (ja) * | 2007-04-27 | 2008-11-13 | Ajinomoto Co., Inc. | ラクタム化合物の結晶形およびその製造方法 |
EP3797775A1 (en) | 2007-10-19 | 2021-03-31 | Novartis AG | Compositions and methods for treatment of diabetic retinopathy |
EP2373640B1 (en) | 2009-01-08 | 2014-07-30 | Merck Patent GmbH | Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof |
EP2801573A1 (en) * | 2013-05-09 | 2014-11-12 | Sanofi | Hydantoine derivatives as CD38 inhibitors |
JP7192262B2 (ja) * | 2018-06-22 | 2022-12-20 | 三菱マテリアル株式会社 | Knn膜形成用液組成物及びこの液組成物を用いたknn膜の形成方法 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1331757C (en) | 1988-02-29 | 1994-08-30 | Janssen Pharmaceutica Naamloze Vennootschap | 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols |
US5346913A (en) | 1992-05-26 | 1994-09-13 | Rohm And Haas Company | N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents |
FR2694290B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
TW521073B (en) | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
FR2741342B1 (fr) | 1995-11-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques |
BR9811260A (pt) | 1997-03-03 | 2000-08-08 | Boehringer Ingelheim Pharma | Pequenas moléculas úteis no tratamento de doença inflamatória |
NZ502872A (en) | 1997-08-28 | 2002-10-25 | Novartis Ag | Mevinolin and compaction as LFA-1 antagonists for treating autoimmune diseases |
AU9802198A (en) | 1997-10-21 | 1999-05-10 | Pharmacia & Upjohn Company | Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors |
AU1083499A (en) | 1997-10-21 | 1999-05-10 | Pharmacia & Upjohn Company | Thiadiazoles amides useful as antiinflammatory agents |
EP1063982B1 (en) | 1998-03-27 | 2007-02-14 | Genentech, Inc. | Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders |
US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
US6110922A (en) | 1998-12-29 | 2000-08-29 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
CO5140104A1 (es) | 1999-02-16 | 2002-03-22 | Novartis Ag | Derivados de mevinolina y preparacion farmaceuticas que los contienen |
UA74781C2 (en) | 1999-04-02 | 2006-02-15 | Abbott Lab | Antiinflammatory and immumosuppressive compounds inhibiting cell adhesion |
WO2001007048A1 (en) | 1999-07-21 | 2001-02-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
WO2001007052A1 (en) | 1999-07-21 | 2001-02-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
US6492408B1 (en) | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
WO2001007044A1 (en) | 1999-07-21 | 2001-02-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
WO2001006984A2 (en) | 1999-07-21 | 2001-02-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
MXPA02003977A (es) | 1999-10-20 | 2003-09-25 | Tanabe Seiyaku Co | Inhibidores de adhesion de celula mediada por al°2. |
AU777721B2 (en) | 2000-01-14 | 2004-10-28 | Larson, Richard | Peptide inhibitors of LFA-1/ICAM-1 interaction |
US6515124B2 (en) | 2000-02-09 | 2003-02-04 | Hoffman-La Roche Inc. | Dehydroamino acids |
AU6872401A (en) | 2000-06-29 | 2002-01-14 | Abbott Lab | Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
AU6871801A (en) | 2000-06-29 | 2002-01-14 | Abbott Lab | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
US7709520B2 (en) | 2000-10-06 | 2010-05-04 | The Texas A&M University System | Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers |
GB0028367D0 (en) | 2000-11-21 | 2001-01-03 | Celltech Chiroscience Ltd | Chemical compounds |
KR20030051882A (ko) | 2000-11-28 | 2003-06-25 | 제넨테크, 인크. | Lfa-1 대항제 화합물 |
WO2002044181A1 (en) | 2000-12-01 | 2002-06-06 | Bristol-Myers Squibb Company | Hydantoin compounds useful as anti-inflammatory agents |
ATE445400T1 (de) | 2001-05-25 | 2009-10-15 | Bristol Myers Squibb Co | Hydantion-derivate als hemmer von matrix- metalloproteinasen |
PL369337A1 (en) | 2001-10-01 | 2005-04-18 | Bristol-Myers Squibb Company | Spiro-hydantoin compounds useful as anti-inflammatory agents |
TW200616634A (en) * | 2004-10-01 | 2006-06-01 | Bristol Myers Squibb Co | Crystalline forms and process for preparing spiro-hydantoin compounds |
-
2005
- 2005-09-28 TW TW094133821A patent/TW200616634A/zh unknown
- 2005-09-29 US US11/238,427 patent/US7381737B2/en active Active
- 2005-09-30 AR ARP050104164A patent/AR052772A1/es unknown
- 2005-09-30 WO PCT/US2005/035467 patent/WO2006039639A1/en active Application Filing
- 2005-09-30 JP JP2007534856A patent/JP2008514729A/ja active Pending
- 2005-09-30 EP EP05812262A patent/EP1802628A1/en not_active Withdrawn
- 2005-10-03 PE PE2005001167A patent/PE20060578A1/es not_active Application Discontinuation
-
2008
- 2008-05-30 US US12/130,915 patent/US20080269499A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20080269499A1 (en) | 2008-10-30 |
TW200616634A (en) | 2006-06-01 |
US20060074099A1 (en) | 2006-04-06 |
US7381737B2 (en) | 2008-06-03 |
PE20060578A1 (es) | 2006-07-09 |
EP1802628A1 (en) | 2007-07-04 |
WO2006039639A1 (en) | 2006-04-13 |
JP2008514729A (ja) | 2008-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR052772A1 (es) | Formas cristalinas y proceso para preparar compuestos de espiro-hidantoina | |
AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
RU2012112050A (ru) | Производные дигидроптеридинона, способ их получения и фармацевтическое применение | |
EA201270636A1 (ru) | Способ получения метил-{4,6-диамино-2-[1-(2-фторбензил)-1н-пиразоло[3,4-в]пиридин-3-ил]пиримидин-5-ил}метилкарбамата и его очистки для применения в качестве фармацевтического биологически активного вещества | |
PE20061198A1 (es) | Derivados de pirazol como inhibidores de cdk y gsk | |
ECSP034848A (es) | Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes | |
PE20080538A1 (es) | Derivado heterociclico fusionado y su uso | |
AR038419A1 (es) | Derivados de piridina y quinolina | |
AR035668A1 (es) | Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos | |
PE20140522A1 (es) | Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
PE20091014A1 (es) | Compuestos espiro y uso farmaceutico de los mismos | |
ES2427894T3 (es) | Aza-indoles y compuestos relacionados que tienen actividad biológica antagonista del receptor de esfingosina-1-fosfato (S1P) | |
RU2012110882A (ru) | Производные 6-аминохиназолина или 3-цианохинолина, способы их получения и их фармацевтические применения | |
CY1109376T1 (el) | Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης | |
AR045082A1 (es) | Compuestos de aminobenzofenona y su uso en tratamientos terapeuticos | |
RU2011121438A (ru) | Алкилциклогексиловые эфиры дигидротетраазабензоазуленов | |
PE20110546A1 (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk) y produccion de los mismos | |
RU2014126341A (ru) | СОЕДИНЕНИЯ ТИЕНИЛ[3, 2-d]ПИРИМИДИН-4-ОН, СПОСОБ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ | |
ES2305139T3 (es) | Derivados de purina condensados como antagonistas de receptores de adenosina a1. | |
US20040006079A1 (en) | Substituted 2,4-dihydro-pyrrolo[3,4-b]quinolin-9-one derivatives useful as phosphodiesterase inhibitors | |
PE20050293A1 (es) | Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos | |
PE20060738A1 (es) | Formas cristalinas de espiro-hidantoina substituidas con piridilo y procesos para su produccion | |
AR041991A1 (es) | Compuestos depirazol para el tratamiento de la hipertension ocular | |
RU2009128968A (ru) | Производные изосорбидмононитрата для лечения повышенной внутриглазной гипертензии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |